EyePoint Pharmaceuticals to Report First Quarter 2021 Financial Results and Discuss Recent Corporate Developments on May 5, 2021

Rhea-AI Summary

EyePoint Pharmaceuticals (NASDAQ: EYPT) is set to host a conference call on May 5, 2021, at 8:30 a.m. ET to announce its Q1 2021 financial results and discuss corporate developments. The call will be accessible via phone and a live webcast on the company’s website. EyePoint focuses on therapeutics for serious eye disorders, utilizing its Durasert® technology for sustained drug delivery. Its commercial products include YUTIQ® for chronic uveitis and DEXYCU® for postoperative inflammation.

Positive

• Upcoming Q1 2021 financial results announcement may indicate company growth.
• Innovative Durasert® technology could enhance treatment options in ophthalmology.

Negative

• None.

WATERTOWN, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, May 5, 2021 to report its first quarter 2021 financial results and discuss recent corporate developments.

To access the live conference call, please dial (877)-312-7507 (domestic) or (631)-813-4828 (international) and reference conference ID 6688397. A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepointpharma.com. A webcast replay will also be available on the corporate website at the conclusion of the call.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc. (Nasdaq:EYPT) is a pharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert® technology for extended intraocular drug delivery including EYP-1901, a potential twice-yearly sustained delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. The Company has two commercial products: YUTIQ®, for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU®, for the treatment of postoperative inflammation following ocular surgery. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts. To learn more about the Company, please visit www.eyepointpharma.com and connect on Twitter and LinkedIn.

Investors:

Christina Tartaglia
Stern IR
Direct: 212-698-8700
christina.tartaglia@sternir.com

Media Contact

Caren Begun
Green Room Communications
Direct: (201) 396-8551
caren@greenroompr.com 

FAQ

When will EyePoint Pharmaceuticals report Q1 2021 financial results?

EyePoint Pharmaceuticals will report its Q1 2021 financial results on May 5, 2021.

How can I access the EyePoint Pharmaceuticals conference call?

The conference call can be accessed by dialing (877)-312-7507 for domestic callers or (631)-813-4828 for international callers, using conference ID 6688397.

What technology does EyePoint Pharmaceuticals utilize for its products?

EyePoint Pharmaceuticals utilizes its proprietary Durasert® technology for extended intraocular drug delivery.

What are the commercial products offered by EyePoint Pharmaceuticals?

EyePoint Pharmaceuticals has two commercial products: YUTIQ® for chronic non-infectious uveitis and DEXYCU® for postoperative inflammation.